CEO Interview: Quick-Med Technologies, Inc. - J. Ladd Greeno

• On 3:35 pm EST, Monday November 2, 2009

67 WALL STREET, New York - November 2, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76-page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Small-Cap Specialty Pharma - Patent Expiration - Pending Health Care Reform - Cultivating And Expanding R&D Pipelines - Chinese Drug Manufacturers - Brisk M&A Activity - Indian Pharma VS. U.S. Pharma - Competition From Generics - FDA Approval Process - Clinical Research Outsourcing Market - Stem Cell-Based Technology - Cancer Radiation Therapy - Expansion Into Asian Markets - Traditional Chinese Medicine VS. Western Medicine In Chinese Pharma

Companies include: Aeolus Pharmaceuticals (AOLS.OB); Nutra Pharma (NPHC.OB); Quick-Med Technologies (QMDT.OB); Abbott Labs (ABT); Alexza Pharmaceuticals (ALXA); AmexDrug Corporation (AXRX.OB); Aurobindo Pharma (AUROBINDOP.BO); BioClinica (BIOC); BioPharm Asia (BFAR.OB); Biocon (BIOCON.BO); Cephalon (CEPH); China Sky One Medical, Inc. (CSKI); Claris Lifesciences (CLARICH.BO); Cortex Pharmaceuticals (COR); Daiichi Sankyo (DSKYF.PK); Dr.Reddy's (RDY); Elan (Elan); Eli Lilly (LLY); Forest (FRX); GeoPharma (GORX); Glaxo (GSK); Glenmark (GLENMARK.BO); Johnson & Johnson (JNJ); Lupin (LUPINSL.BO); Mannatech (MTEX); Matrix Laboratories (ATRIXLAB.BO); Medical Nutrition (MDNU); Merck KGaA (MKGAY.PK); Mylan (MYL); NeoStem (NBS); Novartis (NVS); Pfizer (PFE); Piramal Healthcare (PIRAMALHE.BO); Provectus Pharmaceuticals (PVCT.OB); Ranbaxy (RANBAXY.BO); Salix Pharmaceuticals (SLXP); Shire (SHPGY); Telik (TELK); Winston Pharmaceuticals (WPHM.OB).

In the following brief excerpt from the 76-page report, J. Ladd Greeno, CEO of Quick-Med Technologies, Inc., discusses the outlook for the sector and for investors.

J. LADD GREENO has served as Chief Executive Officer of Quick-Med Technologies, Inc., since August 2007. Throughout his career, he has held significant leadership roles in companies where technology, innovation and entrepreneurial spirit have been leveraged for sustainable growth. Prior to joining Quick-Med, he served as Chairman, CEO and President of Agion Technologies, Inc., a leading provider of silver-based antimicrobial solutions. Previously, he built a highly diversified record of accomplishments during 25 years at Arthur D. Little, Inc., a global management and technology consulting firm. As Chief Operating Officer, Mr. Greeno led ADL's global business operations. Previously, he served as Senior Vice President and Managing Director of ADL's North American management consulting business. Mr. Greeno began his consulting career in the firm's strategy and organization practice, and then built ADL's highly successful global environmental, health and safety consulting business with pioneering work in environmental assurance and sustainability. He received an MBA from Harvard Business School and a BBA from the University of Oklahoma.

TWST: Let's begin with an overview of Quick-Med Technologies, the company's history, products, activities, customers, etc.

Mr. Greeno: Quick-Med Technologies (QMDT.OB) is a life sciences company that's developing innovative technologies for the health care and consumer markets. We have four platform technologies: NIMBUS, which is a unique non-leaching antimicrobial technology that received FDA market clearance in February and is now being commercialized for various medical device applications; Stay Fresh, a new technology that we just announced that represents a highly durable antimicrobial treatment that's been designed to withstand repeated laundering cycles and truly last through the life of a garment; NimbuDerm, a long-lasting, comfortable hand sanitizer barrier technology that provides ongoing protection for hours after application; MultiStat, a family of compound shown to be effective in the maintenance and repair of skin and eye tissues, has been commercialized in the consumer cosmetic market by a large retail chain. Each of our four technologies offers features that we believe are vastly superior to current commercially available products. Quick-Med's NIMBUS technology, cleared by FDA earlier this year, is unique in that it's non-leaching. Most antimicrobials must leach or release their active agent in order to work. Since the NIMBUS antimicrobial agent is bonded to the surface, many of the drawbacks common to other antimicrobials are avoided. NIMBUS does not leach active agent into the body or into the environment, thus improving the safety profile of the materials that are treated with it. And because it doesn't deplete, it remains at full strength and never drops below the minimum inhibitory concentration. That's the point where an antimicrobial stops killing microbes, increasing the likelihood of bacterial resistance. NIMBUS treatment can also be effectively performed at extremely low cost. We've initially targeted wound care applications, where there is strong recognition of the value of antimicrobials. Our first licensee is Derma Sciences, and they introduced their first two products based on our technology in June. We also are partnering with Avery Dennison Corporation under a joint development agreement to develop medical-grade NIMBUS adhesives. We have a joint development agreement with Foster Corporation to develop NIMBUS-based catheters, and we are working in a variety of other medical device applications, including incontinence pads, where we think there'll be demand for a highly effective, non-leaching antimicrobial. We believe that NIMBUS has the potential to significantly enhance public health worldwide because it addresses the bacteria that give rise to infections. NIMBUS is not only highly effective, but it's also very low cost, allowing it to be applied in situations where other antimicrobials are deemed too expensive. Our second platform technology, Stay Fresh, is a remarkable technology that we developed specifically for textile applications. Stay Fresh greatly surpasses the performance of currently available antimicrobial textile treatments. It's both highly effective and highly durable. In fact, it's able to maintain performance through 75 laundering cycles in hot or cold water. This exceptional performance overcomes a major limitation common among today's leading antimicrobial technologies. Stay Fresh represents extraordinary value - superior antimicrobial performance at a fraction of the cost of today's antimicrobials. We plan to initially commercialize Stay Fresh in workwear and commercial uniforms, essential apparel and medical textiles. Our third technology, NimbuDerm, is a derivative of NIMBUS chemistry that's being developed by Quick-Med as a new generation of hand sanitizers. When commercialized, NimbuDerm will not only offer the convenience and rapid action that's come to be expected of an instant hand sanitizer, but also provide continuous long-lasting protection that's currently missing in today's products. Current alcohol-based hand sanitizers provide instant sanitation of hands but without any lasting or continuing protection. In fact, as soon as the alcohol agent evaporates and your hands begin to feel dry - typically in less than 15 seconds - the antimicrobial protection properties vanish, leaving the sanitized hands vulnerable to re-contamination. We believe that persistent antimicrobial protection is important because many common touch surfaces can be contaminated with harmful microbes, and it's simply not practical to wash or even sanitize one's hands after each and every contact with a potentially contaminated surface. NimbuDerm is comfortable; it forms a breathable film barrier that adheres to skin and maintains a protective antimicrobial barrier for your treated hands. Our fourth technology platform, MultiStat, has been shown to be highly effective in key skincare applications for medical and consumer markets. We've partnered with BASF, the world's largest chemical company, who is our exclusive global manufacturing and distribution partner for MultiStat cosmeceutical ingredients. BASF is marketing MultiStat to cosmetic companies. Additionally, we've received two research and development contracts from the U.S. Army, totaling approximately $2 million for the development of MultiStat-based advanced treatments. So that's helping us to extend the capabilities of that technology as well. So that is a quick summary of our four platform technologies.

TWST: What do you consider to be the most appropriate markets for these technologies?

Mr. Greeno: There are four technologies and they're each somewhat different. Three of our technologies control harmful microbes. We believe that there are large unmet market needs, ranging from safer medical devices to germ-free medical textiles, to fresher, odor-free apparel and other functional textile applications, to a more effective approach for hand hygiene.

The Wall Street Transcript is a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs and research analysts. This 76 -page special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online .

The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations.

For Information on subscribing to The Wall Street Transcript, please call 800/246-7673

Buzz up!